Nurix Therapeutics, Inc. (NRIX) Reports In-Line Q3 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Wells Fargo Reiterates Overweight Rating on Nurix (NRIX)
October 15, 2024 6:19 AM EDTWells Fargo analyst Derek Archila reiterated an Overweight rating and $32.00 price target on Nurix (NASDAQ: NRIX)
The analyst comments "Thoughts on the stock. Shares are up +146% vs XBI's +10% YTD. While there is decent value priced in for NX-5948's oppty... More



